Cargando…

Timed walk as primary outcome measure of treatment response in clinical trials for HTLV-1-associated myelopathy: a feasibility study

BACKGROUND: To advance the treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), randomised controlled therapeutic studies with appropriate and sensitive outcomes are reuired. One candidate outcome is the 10-metre walk test (10MWT), a patient-centred, simple and functiona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martin, Fabiola, Inoue, Eisuke, Cortese, Irene C. M., de Almeida Kruschewsky, Ramon, Adonis, Adine, Grassi, Maria Fernanda Rios, Galvão-Castro, Bernardo, Jacobson, Steven, Yamano, Yoshihisa, Taylor, Graham P., Bland, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153909/ https://www.ncbi.nlm.nih.gov/pubmed/27965813 http://dx.doi.org/10.1186/s40814-015-0031-1

Ejemplares similares

Change in timed walk as primary outcome measure of treatment response in HAMLET-P: HAM/TSP MuLticentre Efficacy trial-Prednisolone
por: Martin, Fabiola, et al.
Publicado: (2014)

Comparison of walking measures in patients with HTLV-1 Associated Myelopathy
por: Adonis, Adine, et al.
Publicado: (2015)

Assessing Walking Ability in People with HTLV-1-Associated Myelopathy Using the 10 Meter Timed Walk and the 6 Minute Walk Test
por: Adonis, Adine, et al.
Publicado: (2016)

Incidence of tropical spastic parapesis/ HTLV-1 associated myelopathy/ (TSP/HAM) in patients followed in a Reference center in Salvador, Brasil
por: Teixeira, Izabel Bou, et al.
Publicado: (2015)

Effect of Pulsed Methylprednisolone on Pain, in Patients with HTLV-1-Associated Myelopathy
por: Buell, Kevin G., et al.
Publicado: (2016)

Efficacy of Corticosteroid Therapy for HTLV-1-Associated Myelopathy: A Randomized Controlled Trial (HAMLET-P)
por: Yamauchi, Junji, et al.
Publicado: (2022)

Assessment of functional capacity and flexibility of patients infected with HTLV-1
por: Santos, Isabelle Rocha, et al.
Publicado: (2015)

Using the 6 minute walk to investigate endurance in patients with HTLV associated myelopathy
por: Adonis, A, et al.
Publicado: (2014)

A proof of concept study of Infliximab for the treatment of HTLV-1-associated myelopathy
por: Martin, Fabiola, et al.
Publicado: (2014)

Quality of life (QOL) and depression in HTLV-1 carriers
por: Galvão-Phileto, Ana V, et al.
Publicado: (2011)

Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis
por: Yamakawa, Natsuko, et al.
Publicado: (2020)

Ciclosporin A Proof of Concept Study in Patients with Active, Progressive HTLV-1 Associated Myelopathy/Tropical Spastic Paraparesis
por: Martin, Fabiola, et al.
Publicado: (2012)

Proposal of Classification Criteria for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis Disease Activity
por: Sato, Tomoo, et al.
Publicado: (2018)

Functional capacity of natural killer cells in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) patients
por: Queiroz, Gabriel Andrade Nonato, et al.
Publicado: (2019)

CSF CXCL10, CXCL9, and Neopterin as Candidate Prognostic Biomarkers for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
por: Sato, Tomoo, et al.
Publicado: (2013)

Real-world clinical course of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) in Japan
por: Tsutsumi, Shuntaro, et al.
Publicado: (2019)

Ascorbic Acid Has Superior Ex Vivo Antiproliferative, Cell Death-Inducing and Immunomodulatory Effects over IFN-α in HTLV-1-Associated Myelopathy
por: Moens, Britta, et al.
Publicado: (2012)

Treatment of patients with HTLV-1-associated myelopathy with methotrexate
por: Ahmed, S, et al.
Publicado: (2014)

CXCL10 and neopterin in CSF are candidate prognostic biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis
por: Yamano, Yoshihisa, et al.
Publicado: (2014)

HTLV-1 proviral load as an indicative marker of HAM/TSP: a systematic review of studies of patients with HAM/TSP
por: Bassi, Shiva Shaan, et al.
Publicado: (2014)

CD80(+) and CD86(+) B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis
por: Menezes, Soraya Maria, et al.
Publicado: (2014)

Biomarker to predict treatment response in patients with HTLV-1 associated myelopathy/Tropical spastic paraparesis (HAM/TSP)
por: Tamaki, Keiko, et al.
Publicado: (2015)

Human leukocyte antigen (HLA) class I frequencies in human T-cell lymphotropic virus type 1 (HTLV-1)-infected patients from Salvador-Brazil
por: Olavarria, Viviana N, et al.
Publicado: (2011)

Mortality and risk of progression to adult T cell leukemia/lymphoma in HTLV-1–associated myelopathy/tropical spastic paraparesis
por: Nagasaka, Misako, et al.
Publicado: (2020)

EZH1/2 dual inhibitors suppress HTLV-1-infected cell proliferation and hyperimmune response in HTLV-1-associated myelopathy
por: Koseki, Akihito, et al.
Publicado: (2023)

Susceptibility of Primary HTLV-1 Isolates from Patients with HTLV-1-Associated Myelopathy to Reverse Transcriptase Inhibitors
por: Macchi, Beatrice, et al.
Publicado: (2011)

Prevalence and characteristics of HTLV-associated uveitis in patients from Bahia, an endemic area for HTLV − 1 in Brazil
por: Piai Ozores, Daniele, et al.
Publicado: (2023)

HTLV-1 proviral load of HAM/TSP patients according to new diagnostic criteria of HAM/TSP
por: Grassi, Maria F R, et al.
Publicado: (2011)

HTLV-1 is predominantly sexually transmitted in Salvador, the city with the highest HTLV-1 prevalence in Brazil
por: Nunes, David, et al.
Publicado: (2017)

Effect of pulsed methylprednisolone on disease severity, viral load and inflammation in patients with human T-lymphotropic virus type 1 associated myelopathy
por: Buell, Kevin, et al.
Publicado: (2015)

Proteomic profiling of HTLV-1 infected T-cells for the identification of potential biomarkers and therapeutic targets for HTLV-1 associated myelopathy/ tropical spastic paraparesis and adult T-cell leukemia
por: Ueda, Koji, et al.
Publicado: (2011)

Human T-Lymphotropic Virus Type 1 (HTLV-1) and Regulatory T Cells in HTLV-1-Associated Neuroinflammatory Disease
por: Araya, Natsumi, et al.
Publicado: (2011)

A case of post-transplant adult T-cell leukemia/lymphoma presenting myelopathy similar to but distinct from human T-cell leukemia virus type I (HTLV- I)-associated myelopathy
por: Kawamata, Toyotaka, et al.
Publicado: (2014)

An Evaluation of the Spontaneous Proliferation of Peripheral Blood Mononuclear Cells in HTLV-1-Infected Individuals Using Flow Cytometry
por: Pinto, Lorena Ana, et al.
Publicado: (2011)

Distribution of Human T-Lymphotropic Virus (HTLV) and Hepatitis C Co-infection in Bahia, Brazil
por: Pereira, Felicidade Mota, et al.
Publicado: (2020)

Impaired flexibility in patients with tropical spastic paraparesis/HTLV-associated myelopathy: evaluation via pendulum fleximeter
por: Landim, Caroline, et al.
Publicado: (2023)

Potential role of HTLV-1 Tax-specific cytotoxic t lymphocytes expressing a unique t-cell receptor to promote inflammation of the central nervous system in myelopathy associated with HTLV-1
por: Tanaka, Yukie, et al.
Publicado: (2022)

Immunovirological markers in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)
por: Enose-Akahata, Yoshimi, et al.
Publicado: (2019)

Human T-lymphotropic virus type 1 (HTLV-1) and cellular immune response in HTLV-1-associated myelopathy/tropical spastic paraparesis
por: Nozuma, Satoshi, et al.
Publicado: (2020)

Cerebrospinal Fluid CXCL10 as a Candidate Surrogate Marker for HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis
por: Tamaki, Keiko, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ctch6ip3bro5kaqqntbuqm17li